Arch Biopartners appoints Dr. Patrick Vink as Chairman of the Board

Arch Biopartners announced the appointment of Dr. Patrick Vink as chairman of the board in a press release dated January 16, 2026. The release also contains forward-looking statements about the company's drug-development programs targeting chronic kidney disease and the DPEP-1 pathway.

Arch Biopartners announced the appointment of Dr. Patrick Vink as chairman of the board in a press release dated January 16, 2026. The release presents the leadership change alongside information about the company's ongoing research. It refers to work on drug candidates addressing chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway. The statement includes standard forward-looking disclosures required under Canadian securities laws. Key points: - Arch Biopartners announced Dr. Patrick Vink as chairman of the board. - The press release was published on January 16, 2026. - The release includes forward-looking statements about the company's future performance, liquidity, capital resources, and development plans. - It references drug programs targeting chronic kidney disease and the DPEP-1 pathway, including LSALT peptide (Metablok) and cilastatin. - Additional information about the company is noted as available on the SEDAR+ website. Summary: The company confirmed the leadership appointment and reiterated forward-looking disclosures related to its drug-development programs. Undetermined at this time.